INCA33890 + bevacizumab + folinic acid + fluorouracil + irinotecan

This combination is an investigational multi-agent regimen comprising a bispecific monoclonal antibody (INCA33890), a VEGF-targeting antibody (bevacizumab), and a standard chemotherapeutic backbone commonly used in colorectal and other advanced cancers (folinic acid, fluorouracil, irinotecan). **INCA33890** is a PD-1 x TGFβR2 bispecific Biclonics® antibody that targets and inhibits both PD-1 and TGFβR2 on T cells, aiming to synergistically overcome tumor microenvironment-driven immunosuppression by blocking both immune checkpoint (PD-1/PD-L1) and TGF-β signaling[1][3][5][7]. **Bevacizumab** is a humanized monoclonal antibody that inhibits VEGF-A, reducing tumor angiogenesis[2][4][6]. **Folinic acid (leucovorin)** potentiates the cytotoxic effect of **fluorouracil**, a pyrimidine antimetabolite inhibiting thymidylate synthase and DNA synthesis, while **irinotecan** is a topoisomerase I inhibitor causing DNA strand breaks. The overall regimen is designed for patients with advanced or metastatic solid tumors, including but not limited to ovarian and colorectal cancers, to attack tumors through immunomodulation, anti-angiogenesis, and cytotoxic chemotherapy.

Other names

leucovorin5-fluorouracil5-FUCPT-11CPT11CPT 11